SecBot SecBot
SC 13G ·Filed Nov 13, 2026

RIGL

RIGEL PHARMACEUTICALS INC
NEUTRAL
Impact 3/10
Horizonweeks Processed3d 9h ago SEC0000895421-26-000335
Passive investor 5%+ stake
Actionable Insight • Neutral

Monitor for any future 13D conversion or increased activism from Morgan Stanley, though the 13G certification indicates passive intent. The accumulation by a major financial institution adds to institutional credibility but does not signal a near-term catalyst.

DirectionNeutral
Confidencehigh
Horizonweeks

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Morgan Stanley filed a Schedule 13G disclosing a 6.5% passive stake in Rigel Pharmaceuticals as of September 30, 2026, held primarily through its subsidiary Morgan Stanley Capital Services LLC (5.6%). This is a new passive disclosure by Morgan Stanley, adding to the existing institutional holder base alongside State Street's 4.7% stake reported three days earlier. The filing carries no activist intent and is consistent with routine portfolio management.

Key Financial Metrics

Stake
6.5%
Investor
Morgan Stanley

Key Facts

  • Morgan Stanley disclosed a 6.5% beneficial ownership stake in Rigel Pharmaceuticals as of September 30, 2026.
  • Morgan Stanley Capital Services LLC, a wholly-owned subsidiary, holds 5.6% (1,040,643 shares) of the total.
  • The filing is a new Schedule 13G, not an amendment, and certifies passive intent under Rule 13d-1(b).
  • This follows State Street's 4.7% passive stake filed on November 10, 2026, and prior filings by Soleus Capital and Armistice Capital earlier in 2026.

Financial Impact

Morgan Stanley's aggregate stake of 1,212,656 shares represents 6.5% of Rigel's outstanding shares, valued at approximately $54.5M based on the $838M market cap.

ownership concentration

Risk Factors

  • Morgan Stanley could convert to a 13D if it later seeks to influence management, though no such intent is indicated.
  • The passive nature of the filing limits immediate price impact; the stake is modest relative to Rigel's market cap.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
73% bullish (11 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
SC 13G Filing (Primary)0000895421-26-000335
Exhibit: EXHIBIT_NO.99.2.txt0000895421-26-000335
Document: 0000895421-26-000335-index-headers.html0000895421-26-000335
Document: 0000895421-26-000335-index.html0000895421-26-000335
Document: 0000895421-26-000335.txt0000895421-26-000335

Track record

12 reports on RIGL

Performance horizon

1 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +25.02% at T+60 after the May 12, 2026 report. 2 of 4 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $45.03 Now $43.73 −2.89% settles Feb 12
  2. Nov 13, 20263d ago SC 13G Neutral 3/10 Viewing Entry $44.21 Now $43.73 −1.09% settles Feb 12
  3. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $43.91 Now $43.73 −0.41% settles Feb 8
  4. Nov 5, 202611d ago 8-K Bearish 5/10 Entry $39.65 Now $43.73 −10.29% settles Feb 4
  5. Aug 4, 202614w ago 8-K Mixed 6/10 Entry $40.48 to $50.92 Now $43.73 +8.03% ▲ +25.79% +25.60% vs SPY
  6. Jun 17, 202621w ago 8-K Neutral 4/10 Entry $32.91 to $45.35 Now $43.73 +32.88% ▲ +37.80% +35.91% vs SPY
  7. Jun 11, 202622w ago Institutional Cluster Neutral 3/10 Entry $32.08 to $48.67 Now $43.73 +36.32% ▲ +51.71% +47.32% vs SPY
  8. May 20, 202625w ago 8-K Neutral 2/10 Entry $29.19 to $42.45 Now $43.73 +49.81% ▲ +45.43% +41.13% vs SPY
  9. May 12, 202626w ago 8-K Bullish 7/10 Entry $32.13 to $40.17 Now $43.73 +36.10% ▲ +25.02% +20.59% vs SPY
  10. May 5, 202627w ago 8-K Bearish 7/10 Entry $26.67 to $36.81 Now $43.73 −63.97% ▼ −38.02% −35.96% vs SPY
Showing 10 of 12

US Market Status

Market Closed · Opens in 6h 41m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 13, 2026